| Literature DB >> 29572786 |
Nicola Lamberti1, Alessia Finotti2, Jessica Gasparello2, Ilaria Lampronti2, Christel Zambon1, Lucia Carmela Cosenza2, Enrica Fabbri2, Nicoletta Bianchi2, Francesca Dalla Corte3, Maurizio Govoni3, Roberto Reverberi3, Roberto Gambari4, Fabio Manfredini5.
Abstract
The changes in hemoglobin (Hb) profile following autologous blood transfusion (ABT) for the first time were studied for anti-doping purposes. Twenty-four healthy, trained male subjects (aged 18‒40) were enrolled and randomized into either the transfusion (T) or control (C) groups. Blood samples were taken from the T subjects at baseline, after withdrawal and reinfusion of 450 ml of refrigerated or cryopreserved blood, and from C subjects at the same time points. Hematological variables (Complete blood count, Reticulocytes, Immature Reticulocytes Fraction, Red-cell Distribution Width, OFF-hr score) were measured. The Hb types were analyzed by high-performance liquid chromatography and the Hemoglobin Profile Index (HbPI) arbitrarily calculated. Between-group differences were observed for red blood cells and reticulocytes. Unlike C, the T group, after withdrawal and reinfusion, showed a significant trend analysis for both hematological variables (Hemoglobin concentration, reticulocytes, OFF-hr score) and Hb types (glycated hemoglobin-HbA1c, HbPI). The control charts highlighted samples with abnormal values (> 3-SD above/below the population mean) after reinfusion for hematological variables in one subject versus five subjects for HbA1c and HbPI. A significant ROC-curve analysis (area = 0.649, p = 0.015) identified a HbA1c cut-off value ≤ 2.7% associated to 100% specificity of blood reinfusion (sensitivity 25%). Hemoglobin profile changed in trained subjects after ABT, with abnormal values of HbA1c and HbPI in 42% of subjects after reinfusion. Future studies will confirm the usefulness of these biomarkers in the anti-doping field.Keywords: Biomarkers; Blood transfusion autologous; Doping in Sports; Hemoglobins
Mesh:
Substances:
Year: 2018 PMID: 29572786 DOI: 10.1007/s11739-018-1837-7
Source DB: PubMed Journal: Intern Emerg Med ISSN: 1828-0447 Impact factor: 3.397